Management of Comorbidities in Older Persons With Type 2 Diabetes

Morley, John E.; Abbatecola, Angela Marie; Woo, Jean

doi:10.1016/j.jamda.2017.05.006

Cited by 11 publications

(10 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like frailty, DM is associated with increased disability and mortality in older people ( 7 ). In developed countries, more than half of the population with DM are aged ≥65 years ( 8 ), and it is estimated that the prevalence of frailty is 3-5 fold higher among people with DM than those without ( 9 , 10 ). Alone and in combination, DM and frailty significantly impact health service provision ( 11 ), increasing total healthcare costs ( 12 – 14 ).…”

Section: Introductionmentioning

confidence: 99%

Frailty and diabetes in older adults: Overview of current controversies and challenges in clinical practice

Abd.Ghafar

O’Donovan

Sezgin

et al. 2022

Front. Clin. Diabetes Healthc.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Frailty and diabetes in older adults: Overview of current controversies and challenges in clinical practice

Abd.Ghafar

O’Donovan

Sezgin

et al. 2022

Front. Clin. Diabetes Healthc.

View full text Add to dashboard Cite

show abstract

“…Aging is also associated with many comorbidities such as cognitive dysfunction, neuropathy, renal impairment, and high-risk adverse events such as recurring hypoglycemia. The utility of some therapies, including insulin and sulfonylureas, is limited in geriatric populations by the risk of hypoglycemia [5,6].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies

et al. 2020

View full text Add to dashboard Cite

Introduction: This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged C 60 and \ 60 years. Methods: This post hoc analysis included patients with T2D enrolled in two phase 3 clinical trials AWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582) of dulaglutide 0.75 and 1.5 mg. Patients were Digital Features To view digital features for this article go to

show abstract

“…Therefore, the use of insulin therapy, particularly in elderly patients with T2D diabetes, is limited by the risk of hypoglycaemia. 8 , 9 …”

Section: Introductionmentioning

confidence: 99%

“…Co‐morbidities may affect accurate insulin dosing and insulin clearance, and hypoglycaemic events increase the risk of falls and/or additional cardiovascular‐related morbidity. Therefore, the use of insulin therapy, particularly in elderly patients with T2D diabetes, is limited by the risk of hypoglycaemia 8,9 …”

Section: Introductionmentioning

confidence: 99%

“…Therefore, the use of insulin therapy, particularly in elderly patients with T2D diabetes, is limited by the risk of hypoglycaemia. 8,9 Guideline changes by the American Diabetes Association (ADA) now recommend personalizing treatment for older patients with T2D based on their functional status and co-morbidities. Less stringent glycaemic treatment goals are recommended for frail elderly patients to keep the risk of hypoglycaemia low while also taking co-morbid illness and/or limited life expectancy into consideration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial

Frías

Bonora

Ruiz³

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim To evaluate the efficacy and safety of dulaglutide 3.0 and 4.5 mg versus 1.5 mg when used as an add‐on to metformin in subgroups defined by age (<65 and ≥65 years). Materials and Methods Of 1842 patients included in this post hoc analysis, 438 were aged 65 years or older and 1404 were younger than 65 years. The intent‐to‐treat (ITT) population, while on treatment without rescue medication, was used for all efficacy analyses; the ITT population without rescue medication was used for hypoglycaemia analyses; all other safety analyses used the ITT population. Results Patients aged 65 years or older and those younger than 65 years had a mean age of 69.5 and 53.2 years, respectively. In each age subgroup, the reduction from baseline in HbA1c and body weight (BW), and the proportion of patients achieving a composite endpoint of HbA1c of less than 7% (<53 mmol/mol) with no weight gain and no documented symptomatic or severe hypoglycaemia, were larger for dulaglutide 3.0 and 4.5 mg compared with dulaglutide 1.5 mg, but the treatment‐by‐age interactions were not significant. The safety profile for the additional dulaglutide doses was consistent with that of dulaglutide 1.5 mg and was similar between the age subgroups. Conclusion Dulaglutide doses of 3.0 or 4.5 mg provided clinically relevant, dose‐related improvements in HbA1c and BW with no significant treatment‐by‐age interactions, and with a similar safety profile across age subgroups.

show abstract

Management of Comorbidities in Older Persons With Type 2 Diabetes

Cited by 11 publications

References 75 publications

Frailty and diabetes in older adults: Overview of current controversies and challenges in clinical practice

Frailty and diabetes in older adults: Overview of current controversies and challenges in clinical practice

Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial

Contact Info

Product

Resources

About